APPLICATION OF PHOSPHODIESTERASE TYPE 5 INHIBITORS SILDENAFIL IN PATIENTS WITH PULMONARY HYPERTENSION
The key component of the pathogenesis of pulmonary hypertension (PH) is endothelial dysfunction with imbalance between vasodilators and vasoconstrictors and activation of the blood coagulation system. Randomized trials showed a beneficial effect of phosphodiesterase type 5 (PDE-5) inhibitors on vasc...
主要な著者: | , , , , , |
---|---|
フォーマット: | 論文 |
言語: | Russian |
出版事項: |
InterMedservice
2015-06-01
|
シリーズ: | Евразийский Кардиологический Журнал |
主題: | |
オンライン・アクセス: | https://www.heartj.asia/jour/article/view/5633 |